[{"abstract": "After terminating deals with AstraZeneca and most recently, Allergan, Pfizer has turned to relatively smaller biotech companies for acquisitions.", "web_url": "https://www.nytimes.com/2016/05/17/business/dealbook/pfizer-to-acquire-anacor-pharmaceuticals-for-5-2-billion.html", "snippet": "After terminating deals with AstraZeneca and most recently, Allergan, Pfizer has turned to relatively smaller biotech companies for acquisitions.", "lead_paragraph": "Pfizer has signed its first acquisition since terminating its $152 billion merger with Allergan about a month ago.", "print_section": "B", "print_page": "3", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2016/05/17/business/db-pfizer1/db-pfizer1-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2016/05/17/business/db-pfizer1/db-pfizer1-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2016/05/17/business/db-pfizer1/db-pfizer1-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2016/05/17/business/db-pfizer1/db-pfizer1-superJumbo.jpg", "height": 1366, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2016/05/17/business/db-pfizer1/db-pfizer1-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2016/05/17/business/db-pfizer1/db-pfizer1-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2016/05/17/business/db-pfizer1/db-pfizer1-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "Pfizer to Acquire Anacor Pharmaceuticals for $5.2 Billion", "kicker": null, "content_kicker": null, "print_headline": "Pfizer Refocuses, Scooping Up a Smaller Biotech Company", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Pfizer Inc", "rank": 1, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Anacor Pharmaceuticals Inc", "rank": 4, "major": "N"}], "pub_date": "2016-05-16T12:19:36+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Leslie Picker", "person": [{"firstname": "Leslie", "middlename": null, "lastname": "Picker", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/c34ad3ea-9ee9-5ead-b554-2cf14936d3a6", "word_count": 303, "uri": "nyt://article/c34ad3ea-9ee9-5ead-b554-2cf14936d3a6"}, {"abstract": "The more important question for shareholders, though, is whether Pfizer\u2019s chief executive, Ian C. Read, will break up Pfizer.", "web_url": "https://www.nytimes.com/2016/05/17/business/dealbook/pfizer-could-get-its-moneys-worth-out-of-anacor-deal.html", "snippet": "The more important question for shareholders, though, is whether Pfizer\u2019s chief executive, Ian C. Read, will break up Pfizer.", "lead_paragraph": "Pfizer\u2019s $5.2 billion offer for Anacor Pharmaceuticals, announced on Monday, dodges the drug giant\u2019s bigger issue. The company may have made a good deal for Anacor, the maker of eczema and toenail-fungus remedies, even though it\u2019s paying a 55 percent premium. The more important question for shareholders, though, is whether Pfizer\u2019s chief executive, Ian C. Read, will break up Pfizer.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Pfizer Could Get Its Money\u2019s Worth Out of Anacor Deal", "kicker": "Breakingviews", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 2, "major": "N"}, {"name": "persons", "value": "Read, Ian C", "rank": 3, "major": "N"}, {"name": "organizations", "value": "Anacor Pharmaceuticals Inc", "rank": 4, "major": "N"}], "pub_date": "2016-05-16T18:31:45+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By Antony Currie", "person": [{"firstname": "Antony", "middlename": null, "lastname": "Currie", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/307a3087-4b66-530a-a45b-c061a6c892e5", "word_count": 363, "uri": "nyt://article/307a3087-4b66-530a-a45b-c061a6c892e5"}]